As more and more states legalize the use of marijuana, a product known as CBD oil has surged in popularity. A chemical compound found in the cannabis plant. Cannabidiol, or CBD, is a chemical compound in marijuana with a variety of uses . Here are 7 benefits of CBD oil. Learn more about Cannabidiol uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain Cannabidiol.
CBD Oil Side The Effects of
Research has been able to name it as the least dangerous substance, especially when compared to nicotine and alcohol. When it comes to risks surrounding cannabis use, they all fall within the category of mental illness. THC in particular, which is the psychoactive compound in cannabis, has been linked to psychiatric conditions. It affects the body in a number of different ways, although mostly through the endocannabinoid system. It also can interact with your serotonin receptors.
Like any other substance that you may introduce into your body, CBD does come with its side effects. Most of these trials were centered around mental disorders and epilepsy.
The most common side effects seen from CBD are diarrhea, fatigue, and changes in both appetite and weight. Ultimately, these side effects could be considered minor. The authors of this particular review have said that CBD has low levels of risk compared to other drugs used to treat similar medical issues. Another review that was published in Current Drug Safety journal showed that CBD had no effect on physical symptoms including body temperature, blood pressure, and heart rate.
Most of the side effects associated with CBD have only been witnessed in vitro. This means that they were isolated within a petri dish and subject to animal studies. This means that further research that includes human participants is required to get a better idea of how CBD affects the human body.
Most of the current human studies have included oral administration or inhalation, while in animal studies it was either orally administered or injected. Because the way that CBD is administered determines the levels found in the blood, there can be different outcomes depending on the procedures involved.
This is especially important when talking to patients who take other pharmaceuticals on a regular basis. This means that CBD could potentially affect most medications on the market. Interestingly, this enzyme is also responsible for the break down of CBD in the body.
When mixed with certain pharmaceuticals, the chemical reaction will in some circumstances slow down the metabolizing process, while in others will speed up the process. The International Journal of Neuroscience published a study in that gave CBD to participants who experienced dystonic movement disorders. Oral doses of CBD were given on a daily basis across a period of six weeks.
Improvements in this movement disorder were visible in all patients. However, there were some side effects that were also observed.
These side effects included dry mouth, hypertension, lightheadedness, and sedation. Patients that were administered over mg a day experienced an increase in heart tremors.
This symptom can be quickly taken care of with a glass of juice or water. This symptom happens because CBD decreases the production of saliva in the mouth. When it comes to cannabinoids and questions around dosage, there have been no recorded fatalities. In fact, large daily doses in humans have been tolerated surprisingly well. The Department of Health and Human Services says that there are no severe side effects that can be associated with the regular use of CBD in healthy patients.
One of the keys to avoid side effects is to only use pure CBD oil. Cannabis can help regulate inflammation 2. Marijuana and schizophrenia the debate continues 3. How cannabis may help treat type 2 diabetes. I had no idea that cbd interacts with other drugs. Studies in mice have shown that CBD inactivates cytochrome P isozymes in the short term, but can induce them after repeated administration.
This is similar to their induction by phenobarbital, thereby implying the 2b subfamily of isozymes. Hexobarbital is a CYP2C19 substrate, which is an enzyme that can be inhibited by CBD and can consequently increase hexobarbital availability in the organism.
Recorcinol was also found to be involved in CYP induction. CYP1A1 can be found in the intestine and CBD-induced higher activity could therefore prevent absorption of cancerogenic substances into the bloodstream and thereby help to protect DNA. This means that they do not reduce CBD transport to the brain. The same goes for gefitinib inhibition of Bcrp. These proteins are also expressed at the blood—brain barrier, where they can pump out drugs such as risperidone. This is hypothesized to be a cause of treatment resistance.
Nicardipine was used as the BCRP substrate in the in vitro studies, where the Jar cell line showed the largest increase in BCRP expression correlating with the highest level of transport.
The ex vivo study used the antidiabetic drug and BCRP substrate glyburide. In this study, a dose—response curve should be established in male and female subjects CBD absorption was shown to be higher in women because the concentrations used here are usually not reached by oral or inhaled CBD administration.
Nonetheless, CBD could accumulate in organs physiologically restricted via a blood barrier. Some studies indicate that under certain circumstances, CBD acute anxiolytic effects in rats were reversed after repeated day administration of CBD. Nonetheless, the behavioral tests for OBX-induced hyperactivity and anhedonia related to depression and open field test for anxiety in the CBD-treated OBX animals showed an improved emotional response.
Using microdialysis, the researchers could also show elevated 5-HT and glutamate levels in the prefrontal cortex of OBX animals only. This area was previously described to be involved in maladaptive behavioral regulation in depressed patients and is a feature of the OBX animal model of depression. The fact that serotonin levels were only elevated in the OBX mice is similar to CBD differential action under physiological and pathological conditions. A similar effect was previously described in anxiety experiments, where CBD proved to be only anxiolytic in subjects where stress had been induced before CBD administration.
Elevated glutamate levels have been proposed to be responsible for ketamine's fast antidepressant function and its dysregulation has been described in OBX mice and depressed patients. Chronic CBD treatment did not elicit behavioral changes in the nonoperated mice.
No adverse effects were reported in this study. Various studies on CBD and psychosis have been conducted. The two higher CBD doses had beneficial effects comparable to the atypical antipsychotic drug clozapine and also attenuated the MK effects on the three markers mentioned above. The publication did not record any side effects. One of the theories trying to explain the etiology of bipolar disorder BD is that oxidative stress is crucial in its development.
Whereas CBD did not have an effect on locomotion, it did increase brain-derived neurotrophic factor BDNF levels and could protect against amphetamine-induced oxidative damage in proteins of the hippocampus and striatum. No adverse effects were recorded in this study.
Another model for BD and schizophrenia is PPI of the startle reflex both in humans and animals, which is disrupted in these diseases.
CBD, which is nonhedonic, can reduce heroin-seeking behavior after, for example, cue-induced reinstatement. In addition, the described study was able to replicate previous findings showing no CBD side effects on locomotor behavior. There are various mechanisms underlying neuroprotection, for example, energy metabolism whose alteration has been implied in several psychiatric disorders and proper mitochondrial functioning.
A study comparing acute and chronic CBD administration in rats suggests an additional mechanism of CBD neuroprotection: Mitochondrial activity was measured in the striatum, hippocampus, and the prefrontal cortex.
Since the mitochondrial complexes I and II have been implied in various neurodegenerative diseases and also altered ROS reactive oxygen species levels, which have also been shown to be altered by CBD, this might be an additional mechanism of CBD-mediated neuroprotection.
In healthy cells, this can be interpreted as a way to protect against the higher ROS levels resulting from more mitochondrial activity. Another publication studied the difference of acute and chronic administration of two doses of CBD in nonstressed mice on anxiety.
Already an acute i. Fifteen days of repeated i. However, the higher dose caused a decrease in neurogenesis and cell proliferation, indicating dissociation of behavioral and proliferative effects of chronic CBD treatment.
The study does not mention adverse effects. Numerous studies show the CBD immunomodulatory role in various diseases such as multiple sclerosis, arthritis, and diabetes. These animal and human ex vivo studies have been reviewed extensively elsewhere, but studies with pure CBD are still lacking. It would be especially interesting to study when CBD is proinflammatory and under which circumstances it is anti-inflammatory and whether this leads to side effects Burstein, Table 1 shows a summary of its anti-inflammatory actions; McAllister et al.
In case of Alzheimer's disease AD , studies in mice and rats showed reduced amyloid beta neuroinflammation linked to reduced interleukin [IL]-6 and microglial activation after CBD treatment.
This led to amelioration of learning effects in a pharmacological model of AD. The chronic study we want to describe in more detail here used a transgenic mouse model of AD, where 2.
CBD was able to prevent the development of a social recognition deficit in the AD transgenic mice. Using statistical analysis by analysis of variance, this was shown to be only a trend.
This might have been caused by the high variation in the transgenic mouse group, though. This was probably due to already elevated cholesterol in the transgenic mice. The study observed no side effects. After CBD treatment was stopped, observation continued until the mice were 24 weeks old. CBD increased IL levels, which is thought to act as an anti-inflammatory cytokine in this context. After inducing arthritis in rats using Freund's adjuvant, various CBD doses 0.
CBD reduced joint swelling, immune cell infiltration. CBD was shown to be able to influence migratory behavior in cancer, which is also an important aspect of embryogenesis.
Helix-loop-helix Id proteins play a role in embryogenesis and normal development via regulation of cell differentiation. High Id1-levels were also found in breast, prostate, brain, and head and neck tumor cells, which were highly aggressive. In contrast, Id1 expression was low in noninvasive tumor cells. Id1 seems to influence the tumor cell phenotype by regulation of invasion, epithelial to mesenchymal transition, angiogenesis, and cell proliferation.
There only seems to exist one study that could not show an adverse CBD effect on embryogenesis. An in vitro study could show that the development of two-cell embryos was not arrested at CBD concentrations of 6.
Various studies have been performed to study CBD anticancer effects. CBD every 3 days for a total of 28 weeks, almost completely reduced the development of metastatic nodules caused by injection of human lung carcinoma cells A in nude mice. The typical side effects of traditional anticancer medication, emesis, and collateral toxicity were not described in these studies. Consequently, CBD could be an alternative to other MMP1 inhibitors such as marimastat and prinomastat, which have shown disappointing clinical results due to these drugs' adverse muscoskeletal effects.
Two studies showed in various cell lines and in tumor-bearing mice that CBD was able to reduce tumor metastasis. CBD downregulated Id1 at promoter level and reduced tumor aggressiveness.
Moreover, to carry out these experiments, animals are often immunologically compromised, to avoid immunogenic reactions as a result to implantation of human cells into the animals, which in turn can also affect the results.
Another approach was chosen by Aviello et al. After 3 months, the number of aberrant crypt foci, polyps, and tumors was analyzed. The high CBD concentration led to a significant decrease in polyps and a return to near-normal levels of phosphorylated Akt elevation caused by the carcinogen.
Animal studies summarized by Bergamaschi et al. Chronic administration 14 days, 2. This effect could be inhibited by coadministration of a CB2R antagonist. The positive effects of CBD on hyperglycemia seem to be mainly mediated via CBD anti-inflammatory and antioxidant effects.
In addition, treatment increased adiponectin and liver glycogen concentrations. CBD showed inhibition of testosterone oxidation in the liver. Motor function was also tested on a rotarod, which was also not affected by CBD administration. Static beam performance, as an indicator of sensorimotor coordination, showed more footslips in the CBD group, but CBD treatment did not interfere with the animals' speed and ability to complete the test. Compared to other anticonvulsant drugs, this effect was minimal.
CBD did not lead to adverse effects. In addition, psychomotor function and psychological functions were not disturbed. Interestingly, the CYP2C19 inhibitor omeprazole, used to treat gastroesophageal reflux, could not significantly affect the pharmacokinetics of CBD. Unfortunately, it was not mentioned whether this effect was mediated via the cytochrome P complex. Another aspect, which has not been thoroughly looked at, to our knowledge, is that several cytochrome isozymes are not only expressed in the liver but also in the brain.
It might be interesting to research organ-specific differences in the level of CBD inhibition of various isozymes. Apart from altering the bioavailability in the overall plasma of the patient, this interaction might alter therapeutic outcomes on another level. Generally, more human studies, which monitor CBD-drug interactions, are needed. In a double-blind, placebo-controlled crossover study, CBD was coadministered with intravenous fentanyl to a total of 17 subjects.
This was followed by a single 0. This extensive tool tests, for example, 78 adverse effects divided into 23 categories corresponding to organ systems or body parts. No respiratory depression or cardiovascular complications were recorded during any test session. The results of the evaluation of pharmacokinetics, to see if interaction between the drugs occurred, were as follows.
No effect was evident for urinary CBD and metabolite excretion except at the higher fentanyl dose, in which CBD clearance was reduced. Importantly, fentanyl coadministration did not produce respiratory depression or cardiovascular complications during the test sessions and CBD did not potentiate fentanyl's effects. No correlation was found between CBD dose and plasma cortisol levels.
CBD did not worsen the adverse effects e. Coadministration was safe and well tolerated, paving the way to use CBD as a potential treatment for opioid addiction.
A Dutch study compared subjective adverse effects of three different strains of medicinal cannabis, distributed via pharmacies, using VAS. The 12 adjectives used for this study were as follows: This strain showed significantly lower levels of anxiety and dejection. Moreover, appetite increased less in the high CBD strain. The review by Bergamaschi et al. This holds especially true for the extrapyramidal motor side effects elicited by classical antipsychotic medication.
Order of drug administration was pseudorandomized across subjects, so that an equal number of subjects received any of the drugs during the first, second, or third session in a double-blind, repeated-measures, within-subject design. This effect was caused by opposite neural activation of relevant brain areas. In addition, no effects on peripheral cardiovascular measures such as heart rate and blood pressure were measured.
A randomized, double-blind, crossover, placebo-controlled trial was conducted in 16 healthy nonanxious subjects using a within-subject design. The doses were selected to only evoke neurocognitive effects without causing severe toxic, physical, or psychiatric reactions. The physiological parameters, heart rate and blood pressure, were also monitored and no significant difference between the placebo and the CBD group was observed. A case study describes a patient treated for cannabis withdrawal according to the following CBD regimen: Hepatic enzymes were also measured daily, but no effect was reported.
Naturalistic studies with smokers inhaling cannabis with varying amounts of CBD showed that the CBD levels were not altering psychomimetic symptoms. CBD might work to alleviate disorders of addiction, by altering the attentive salience of drug cues. The study did not further measure side effects. CBD can also reduce heroin-seeking behaviors e. This was shown in the preclinical data mentioned earlier and was also replicated in a small double-blind pilot study with individuals addicted to opioids, who have been abstinent for 7 days.
One hour after the video session, subjective craving was already reduced after a single CBD administration. The effect persisted for 7 days after the last CBD treatment. Interestingly, anxiety measures were also reduced after treatment, whereas no adverse effects were described. A pilot study with 24 subjects was conducted in a randomized, double-blind, placebo-controlled design to evaluate the impact of the ad hoc use of CBD in smokers, who wished to stop smoking. Pre- and post-testing for mood and craving of the participants was executed.
Craving was assessed using the Tiffany Craving Questionnaire On day 1 and 7, exhaled CO was measured to test smoking status. Sedation, depression, and anxiety were evaluated with the MRS. At day 7, the anxiety levels for placebo and CBD group did not differ.
CBD did not increase depression in contrast to the selective CB1 antagonist rimonabant. CBD might weaken the attentional bias to smoking cues or could have disrupted reconsolidation, thereby destabilizing drug-related memories.
To the best of our knowledge, no acute studies were performed that solely concentrated on CBD glycemic effects.
Moreover, the only acute study that also measured CBD effect on appetite was the study we described above, comparing different cannabis strains. Growth hormone and prolactin levels were unchanged.
Compared to the healthy individuals, the cortisol levels increased less after TSST in the 32 at-risk individuals. The CBD group showed less reduced cortisol levels but differences were not significant. Truly chronic studies with CBD are still scarce. Nonetheless, we also included these studies with repeated CBD treatment, because we think that compared to a one-time dose of CBD, repeated CBD regimens add value and knowledge to the field and therefore should be mentioned here.
These results are supported by another study described in the review by Grotenhermen et al. CBD was administered on average with three other drugs, including clobazam The coadministration led to an alteration of blood levels of several antiepileptic drugs.
In the case of clobazam this led to sedation, and its levels were subsequently lowered in the course of the study. A first pilot study in healthy volunteers in by Mincis et al. Clinical chronic lasting longer than a couple of weeks studies in humans are crucial here but were mostly still lacking at the time of writing this review. They hopefully will shed light on the inconsistencies observerd in animal studies. Chronic studies in humans may, for instance, help to test whether, for example, an anxiolytic effect always prevails after chronic CBD treatment or whether this was an artifact of using different animal models of anxiety or depression.
In a 4-week open trial, CBD was tested on Parkinson's patients with psychotic symptoms. This led to a reduction of their psychotic symptoms. Moreover, no serious side effects or cognitive and motor symptoms were reported. No adverse effects were observed and her symptoms improved. The same positive outcome was registered in another study described by Bergamaschi et al.
The respective treatment was maintained for three additional weeks. This was the case for three patients in the CBD group and five patients in the amisulpride group. CBD treatment was accompanied by a substantial increase in serum anandamide levels, which was significantly associated with clinical improvement, suggesting inhibition of anandamide deactivation via reduced FAAH activity.
In addition, the FAAH substrates palmitoylethanolamide and linoleoyl-ethanolamide both lipid mediators were also elevated in the CBD group. CBD showed less serum prolactin increase predictor of galactorrhoea and sexual dysfunction , fewer extrapyramidal symptoms measured with the Extrapyramidal Symptom Scale, and less weight gain.
Moreover, electrocardiograms as well as routine blood parameters were other parameters whose effects were measured but not reported in the study. CBD better safety profile might improve acute compliance and long-term treatment adherence. A press release by GW Pharmaceuticals of September 15th, , described 88 patients with treatment-resistant schizophrenic psychosis, treated either with CBD in addition to their regular medication or placebo.
Important clinical parameters improved in the CBD group and the number of mild side effects was comparable to the placebo group. Moreover, neurological and physiological examinations were performed, which neither showed signs of CBD toxicity nor severe side effects.
The study also illustrated that CBD was well tolerated. CBD in addition to their regular epilepsy medication. Another clinical study lasting at least 3 months with children and young adults with various forms of epilepsy, who were treated with the CBD drug Epidiolex, was presented at the American Academy for Neurology in In a few cases, severe side effects occurred, but it is not clear, if these were caused by Epidiolex. The largest CBD study conducted thus far was an open-label study with Epidiolex in patients mainly children, the average age of the participants was 11 suffering from severe epilepsy, who could not be treated sufficiently with standard medication.
Ten percent of the patients reported side effects tiredness, diarrhea, and exhaustion. After extensive literature study of the available trials performed until September , CBD side effects were generally mild and infrequent. The only exception seems to be a multicenter open-label study with a total of patients aged 1—30 years, with treatment-resistant epilepsy. This led to a reduction in seizure frequency. It is therefore difficult to put the side effect frequency into perspective.
Attributing the side effects to CBD is also not straightforward in severely sick patients. Thus, it is not possible to draw reliable conclusions on the causation of the observed side effects in this study. This rating instrument comprised the following factors: This assessment instrument analyzes adverse medication effects, including psychic, neurologic, autonomic, and other manifestations. Using various safety outcome variables, clinical tests, and the cannabis side effect inventory, it was shown that there were no differences between the placebo group and the CBD group in the observed side effects.
The occurrence of various degrees of GVHD was compared with historical data from patients, who had only received the standard treatment. This resulted in lower resistin levels compared to baseline.
Everything you need to know about CBD oil
CBD oil is legal in 30 states where medicinal and/or recreational both the quality of CBD oil being produced and its potential side effects, the. CBD Oil. Most of the side effects regarding CBD have been witnessed in vitro ( outside a living organism, such as petri dishes) and in animal. What medical cannabis oil side effects are there, and how common are they Medical cannabis oils, particularly CBD oils, have been known to.